MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Home・Akciju saraksts・MannKind Corp

MannKind Corp

Slēgts

SektorsVeselības aprūpe

2.56 0.79

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.42

Max

2.57

Galvenie mērījumi
By Trading Economics
Ienākumi	-24M -16M
Pārdošana	30M 112M
P/E Sektora vidējais	128 66.418
EPS	0.01
Peļņas marža	-14.245
Darbinieki	591
EBITDA	-20M -2.5M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+192% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-768M 789M
Iepriekšējā atvēršanas cena	1.77
Iepriekšējā slēgšanas cena	2.56

Ziņu noskaņojums

By Acuity

100%

332 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

4.079 / 4.323 Atbalsts un pretestība

MannKind Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. apr. 17:26 UTC

Galvenie ziņu notikumi

EIA Raises Oil-Price Forecasts as War in Middle East Continues

2026. g. 7. apr. 23:55 UTC

Tirgus saruna

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

2026. g. 7. apr. 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Market Talk Roundup: Latest on U.S. Politics

2026. g. 7. apr. 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

2026. g. 7. apr. 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

2026. g. 7. apr. 23:42 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 7. apr. 23:42 UTC

Tirgus saruna

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

2026. g. 7. apr. 23:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

2026. g. 7. apr. 23:15 UTC

Tirgus saruna

Galvenie ziņu notikumi

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

2026. g. 7. apr. 23:04 UTC

Galvenie ziņu notikumi

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

2026. g. 7. apr. 23:04 UTC

Galvenie ziņu notikumi

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

2026. g. 7. apr. 23:03 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. apr. 23:03 UTC

Tirgus saruna

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

2026. g. 7. apr. 23:01 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

2026. g. 7. apr. 22:58 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

2026. g. 7. apr. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

2026. g. 7. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 7. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 7. apr. 19:45 UTC

Tirgus saruna

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

2026. g. 7. apr. 19:17 UTC

Galvenie ziņu notikumi

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

2026. g. 7. apr. 19:16 UTC

Tirgus saruna

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

2026. g. 7. apr. 19:07 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 7. apr. 19:07 UTC

Tirgus saruna

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

2026. g. 7. apr. 18:41 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

2026. g. 7. apr. 18:40 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

2026. g. 7. apr. 18:39 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

2026. g. 7. apr. 18:24 UTC

Galvenie ziņu notikumi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026. g. 7. apr. 17:08 UTC

Tirgus saruna

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

2026. g. 7. apr. 16:21 UTC

Galvenie ziņu notikumi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026. g. 7. apr. 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

MannKind Corp Prognoze

Cenas mērķis

By TipRanks

192% augšup

Prognoze 12 mēnešiem

Vidējais 7.3 USD 192%

Augstākais 10 USD

Zemākais 3.5 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MannKind Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam MannKind Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.079 / 4.323Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Noskaņojums

By Acuity

332 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.